• Qlife shareholders will vote around December 1, 2026, on a directed issue of shares and warrants raising initially up to SEK 3.5 million.
• Major shareholder JEQ Capital proposes the issue for directors, management and certain consultants, viewing it as preferable to a rights issue.
• The subscription price will match the accelerated bookbuilding price for a separate directed issue targeting initially approximately SEK 6 million.
• The meeting is conditional on the board resolving to proceed with the separate issue; passage requires 90% of votes cast and shares represented.
• Proceeds will support development-program preparations, Egoo PHE regulatory approval and launch preparations, and additional pharmaceutical partnerships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20261111:BIT:8059:0) on November 11, 2026, and is solely responsible for the information contained therein.